Abstract:

Objective To evaluate the efficacy and safety of S-1 combined with transarterial infusion with oxaliplatin and embolism therapy for treating advanced gastric cancer. Methods Patients with advanced gastric cancer（n=59） were divided into two groups：30 patients received S-1 orally as well as transarterial chemoembolization with oxaliplatin，while 29 patients in the control group received transarterial chemoembolization with oxaliplatin and fluorouracil，once every 6 weeks. Efficacy and toxicity were evaluated after two treatments. Results The remission rate was 50.0% in the S-1 group and 44.8% in the control group. The disease control rate was significantly higher in the S-1 group（93.3%） than in the control group （68.9%，P<0.05），and median time to progression was longer in the S-1 group （8.1 vs 5.3 months，P<0.05）. Median overall survival was slightly higher in the S-1 group（14.3 vs 13.2 months）. Similar proportions of patients in both groups experienced embolism syndrome（P>0.05），whereas significantly lower proportions of S-1 patients eperienced leucopenia（62.1% vs 33.3%） and diarrhea（51.7% vs 20%，P<0.05）. Conclusion S-1 combined with transarterial infusion of oxaliplatin and embolism shows better efficacy and fewer adverse reactions in patients with advanced gastric cancer than transarterial chemoembolization with oxaliplatin and fluorouracil. These results indi-cate the need for further clinical studies.

Key words: Advanced gastric neoplasm, S-1, Oxaliplatin, Transarterial infusion, Embolism, Efficacy